Nasdaq:US$16.94 (-0.01) | HKEX:HK$26.65 (-0.20) | AIM:£2.80 (+0.02)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 29 Feb 2008

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

1 items
a080229